Minzasolmin (UCB0599)
Mid-stage
completed
completed
CT.gov grounded
Parkinson's program with direct mechanistic relevance to alpha-synuclein biology rather than only symptomatic management.
Program overview
- Mechanism
- alpha-synuclein misfolding inhibition
- Modality
- small molecule
- Phase
- Mid-stage
- Status
- completed
- Recruitment
- completed
- Confidence
- medium
- Watch priority
- 3
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- UCB
- Trial IDs
- NCT04658186, NCT05543252
ClinicalTrials.gov exact matches: NCT04658186, NCT05543252
Regions and recruitment
United States
Canada
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
Indication tags
Parkinson's
alpha-synuclein
Milestones and catalysts
- Last milestone
- A genuine alpha-synuclein small-molecule effort that still matters as a field reference even after the extension study termination.
- Next expected catalyst
- Mostly interpretive now, but still important for understanding how far small-molecule alpha-syn strategies can go.
Related pages
Disease hub
Parkinson's disease hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Mid-stage
active
active, not recruiting
A genetically targeted Parkinson's program that fits the monitor's mechanism-first framing well.
- Mechanism
- GCase pathway modulation
- Modality
- small molecule
- Next catalyst
- Further efficacy and pharmacodynamic data in GBA-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Early / Mid-stage
active
active, not recruiting
Gene-therapy Parkinson's program that gives the watchlist a cleaner exact-grounded GBA1 entry.
- Mechanism
- GBA1 gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Further safety and biomarker interpretation in GBA1-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Mid-stage
active
recruiting
High-visibility Parkinson's program targeting alpha-synuclein pathology.
- Mechanism
- anti-alpha-synuclein antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further progression and functional readouts.
- Last verified
- 20 Apr 2026
Mid-stage
completed
completed
Mechanism-led repurposing program that keeps the Parkinson's pipeline from being only antibody and device narratives.
- Mechanism
- glucocerebrosidase support / lysosomal modulation
- Modality
- small molecule repurposing
- Next catalyst
- Whether clinical and biomarker read-throughs justify a larger disease-modification push.
- Last verified
- 20 Apr 2026
Recent program changes
Minzasolmin (UCB0599)
Added to the monitor: Minzasolmin (UCB0599) · Parkinson's disease · Mid-stage.